Uterine Tamponade Effectively Prevents Maternal Hemorrhaging
|
By HospiMedica International staff writers Posted on 15 Jan 2020 |

Image: An intrauterine balloon tamponade device (Photo courtesy of Alpha Image)
Uterine balloon tamponade (UBT) has an extremely high success rate for treating severe postpartum hemorrhage (PPH), according to a new study.
Researchers at Boston Medical Center (BMC; MA, USA), the University of Campinas (Brazil), Massachusetts General Hospital (MGH; Boston, USA), and other institutions conducted a review of randomized controlled trials, non-randomized studies, and case series through May 2019 that reported on the efficacy, effectiveness, and/or safety of UBT in women with PPH. In all 91 studies (involving 4,729 women) were analyzed to calculate the pooled success rate and relative risk (RR) in studies that included a comparative arm.
The resulted showed that pooled UBT success rate was 85.9%, with the highest rates corresponding to uterine atony (87.1%) and placenta previa (86.8%), and the lowest to placenta accreta spectrum (66.7%) and retained products of conception (76.8%). The results also showed that UBT success rate was lower in cesarean deliveries (81.7%) than in vaginal deliveries (87%). Overall, the frequency of complications attributed to UBT implementation was less than 6.5%. The study was published on January 6, 2020, in the American Journal of Obstetrics & Gynecology.
“It is exquisitely clear that in many areas of the world, maternal mortality drops significantly when UBT is used. But there are still places where one in six women lose their lives from pregnancy-related causes. It's an embarrassment to humankind,” said senior author Thomas Burke, MD, director of the Global Health Innovation Lab at MGH. “There's no question the device works fine. We need to study how to integrate the device into a health system so that good uptake, appropriate use, and best practice result in quality care.”
Postpartum hemorrhage is the leading direct cause of maternal death worldwide. UBT is a minimally invasive intervention that involves inserting an expandable balloon into the uterus and incrementally filling it with liquid, which applies pressure to the uterus until the bleeding stops. Even when it cannot completely control severe PPH, it can still serve a critical role by reducing blood loss until the woman can be transported to a facility with surgical management and other treatment options.
Related Links:
Boston Medical Center
University of Campinas
Massachusetts General Hospital
Researchers at Boston Medical Center (BMC; MA, USA), the University of Campinas (Brazil), Massachusetts General Hospital (MGH; Boston, USA), and other institutions conducted a review of randomized controlled trials, non-randomized studies, and case series through May 2019 that reported on the efficacy, effectiveness, and/or safety of UBT in women with PPH. In all 91 studies (involving 4,729 women) were analyzed to calculate the pooled success rate and relative risk (RR) in studies that included a comparative arm.
The resulted showed that pooled UBT success rate was 85.9%, with the highest rates corresponding to uterine atony (87.1%) and placenta previa (86.8%), and the lowest to placenta accreta spectrum (66.7%) and retained products of conception (76.8%). The results also showed that UBT success rate was lower in cesarean deliveries (81.7%) than in vaginal deliveries (87%). Overall, the frequency of complications attributed to UBT implementation was less than 6.5%. The study was published on January 6, 2020, in the American Journal of Obstetrics & Gynecology.
“It is exquisitely clear that in many areas of the world, maternal mortality drops significantly when UBT is used. But there are still places where one in six women lose their lives from pregnancy-related causes. It's an embarrassment to humankind,” said senior author Thomas Burke, MD, director of the Global Health Innovation Lab at MGH. “There's no question the device works fine. We need to study how to integrate the device into a health system so that good uptake, appropriate use, and best practice result in quality care.”
Postpartum hemorrhage is the leading direct cause of maternal death worldwide. UBT is a minimally invasive intervention that involves inserting an expandable balloon into the uterus and incrementally filling it with liquid, which applies pressure to the uterus until the bleeding stops. Even when it cannot completely control severe PPH, it can still serve a critical role by reducing blood loss until the woman can be transported to a facility with surgical management and other treatment options.
Related Links:
Boston Medical Center
University of Campinas
Massachusetts General Hospital
Latest Patient Care News
- Wearable Sleep Data Predict Adherence to Pulmonary Rehabilitation
- Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care
- VR Training Tool Combats Contamination of Portable Medical Equipment
- Portable Biosensor Platform to Reduce Hospital-Acquired Infections
- First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds
- Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

- Game-Changing Innovation in Surgical Instrument Sterilization Significantly Improves OR Throughput
- Next Gen ICU Bed to Help Address Complex Critical Care Needs
- Groundbreaking AI-Powered UV-C Disinfection Technology Redefines Infection Control Landscape
- Clean Hospitals Can Reduce Antibiotic Resistance, Save Lives
- Smart Hospital Beds Improve Accuracy of Medical Diagnosis
- New Fast Endoscope Drying System Improves Productivity and Traceability
- World’s First Automated Endoscope Cleaner Fights Antimicrobial Resistance
- Portable High-Capacity Digital Stretcher Scales Provide Precision Weighing for Patients in ER
- Portable Clinical Scale with Remote Indicator Allows for Flexible Patient Weighing Use
- Innovative and Highly Customizable Medical Carts Offer Unlimited Configuration Possibilities
Channels
Artificial Intelligence
view channel
Machine Learning Approach Enhances Liver Cancer Risk Stratification
Hepatocellular carcinoma, the most common form of primary liver cancer, is often detected late despite targeted surveillance programs. Current screening guidelines emphasize patients with known cirrhosis,... Read more
New AI Approach Monitors Brain Health Using Passive Wearable Data
Brain health spans cognitive and emotional functions and can fluctuate even in adults without diagnosed disease. Detecting early changes remains difficult in routine care and burdens specialty services... Read moreCritical Care
view channel
Automated IV Labeling Solution Improves Infusion Safety and Efficiency
Medication administration in high-acuity settings is often complicated by multiple concurrent infusions, making accurate line identification essential. In a 10-hospital intensive care unit study, 60% of... Read more
First-Of-Its-Kind AI Tool Detects Pulmonary Hypertension from Standard ECGs
Pulmonary hypertension is a progressive, life‑threatening disease that is frequently missed early because symptoms such as dyspnea are nonspecific and diagnostic delays can exceed two years.... Read moreSurgical Techniques
view channel
Continuous Monitoring with Wearables Enhances Postoperative Patient Safety
Postoperative hypoxemia on general surgical wards is common and often missed by intermittent vital sign checks. Undetected low oxygen levels can delay recovery and raise the risk of complications that... Read more
New Approach Enables Customized Muscle Tissue Without Biomaterial Scaffolds
Volumetric muscle loss is a traumatic loss of skeletal muscle that often leads to permanent functional impairment and limited reconstructive options. Current experimental strategies struggle to deliver... Read moreHealth IT
view channel
EMR-Based Tool Predicts Graft Failure After Kidney Transplant
Kidney transplantation offers patients with end-stage kidney disease longer survival and better quality of life than dialysis, yet graft failure remains a major challenge. Although a successful transplant... Read more
Printable Molecule-Selective Nanoparticles Enable Mass Production of Wearable Biosensors
The future of medicine is likely to focus on the personalization of healthcare—understanding exactly what an individual requires and delivering the appropriate combination of nutrients, metabolites, and... Read moreBusiness
view channel







